PharmaCielo Receives Approval For US$3 Million Import Contract

PharmaCielo Ltd (TSXV: PCLO) has become one of the first venture listed equities to receive approval for the importation of cannabidiol isolate to the United States. The company announced this morning that the exchange has finally granted the approval, which will allow the company to fulfill its previously announced supply agreement.

The supply agreement, announced in late September 2019, was anticipated to be fulfilled by the end of the year as per the original text of the release. This was delayed however as a result of requiring exchange approval for the transaction. The contract stipulates that medicinal grade CBD isolate was to be provided to General Extract, LLC.

In total, the contract itself is for US$3 million, which marks the firms entry to the American market in a significant way. The isolate, which conforms to US Farm Bill standards, is expected to begin arriving in the current quarter to the supplier, with all product being shipped from Columbia.

The venture exchange has approved the company for the importation of up to US$3.0 million in hemp derived CBD isolate to the United States. Any further quantities will require addition venture approval.

PharmaCielo last traded at $3.54 on the TSX Venture.


Information for this briefing was found via Sedar and PharmaCielo Ltd. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

The Goal is Gold Production as Soon as Possible! | Gordon Robb – ESGOLD Corp.

Snowline Gold: The Multi Billion Dollar Valley PEA

Euro Sun: Rovina Copper-Gold Project Secures Some Major Funding

Recommended

Antimony Resources Drills 4.17% Antimony Over 7.4 Metres At Bald Hill

ESGold To Expand Mine Building At Montauban In Advance Of Gold & Silver Production

Related News

PharmaCielo Records $0.4 Million In Revenue, $7.2 Million Net Loss In Q2 2021

PharmaCielo Ltd. (TSXV: PCLO) reported today its financial performance for the quarter ending June 30,...

Friday, August 20, 2021, 09:08:00 AM

PharmaCielo Struggles To Complete Financing, Extends Closing To March

It appears that PharmaCielo (TSXV: PCLO) is having a difficult time raising funds for its...

Friday, February 4, 2022, 08:22:08 AM

PharmaCielo Third Quarter Revenues Crater 97.9%, CEO Forced Out

PharmaCielo Ltd (TSXV: PCLO) this morning filed its third quarter financial results, posting brutal revenues...

Monday, November 30, 2020, 08:34:11 AM

PharmaCielo Conducts $4.0 Million Bought Deal Financing

PharmaCielo Ltd (TSXV: PCLO) is the latest firm to announce a bought deal financing. The...

Wednesday, June 10, 2020, 08:32:24 AM

Stifel Reinitiates Coverage On Eight Cannabis Operators

Earlier this week, Stifel released a new report on cannabis operations, focused predominantly on US-based...

Friday, July 24, 2020, 03:30:00 PM